Report overview
COPD drugs is a medicine used to treatment chronic obstructive pulmonary disease, such as bronchodilators, pde-4 inhibitors? steroids, combination therapies, etc.
This report aims to provide a comprehensive presentation of the global market for COPD Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding COPD Drugs. This report contains market size and forecasts of COPD Drugs in global, including the following market information:
Global COPD Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global COPD Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
One of the emerging trends propelling the growth prospects for this market is the augmented focus and use of combination therapies to treat COPD. Combination therapies are increasingly becoming the preferred choice of treatment as they have better efficacy than monotherapy drugs.
We surveyed the COPD Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global COPD Drugs Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global COPD Drugs Market Segment Percentages, by Type, 2022 (%)
Bronchodilators
PDE-4 Inhibitors
Steroids
Combination Therapies
Others
Global COPD Drugs Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global COPD Drugs Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Others
Global COPD Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global COPD Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies COPD Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies COPD Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Novartis
GlaxoSmithKline
Merck
Abbott Laboratories
Boehringer Ingelheim
AstraZeneca
Roche Holding AG
Teva Pharmaceutical Industries
Vectura Group
Mylan NV
Outline of Major Chapters:
Chapter 1: Introduces the definition of COPD Drugs, market overview.
Chapter 2: Global COPD Drugs market size in revenue.
Chapter 3: Detailed analysis of COPD Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of COPD Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
